SCHEMBL10019245

SCHEMBL10019245

N#Cc1cccc(SCCI)c1

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HSD17B10 Q99714 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
MAOA P21397 5/20 0.41
MAOB P27338 5/20 0.41
CYP19A1 P11511 3/20 0.40
GSK3B P49841 2/20 0.40
ENPP2 Q13822 1/20 0.38
KIF11 P52732 1/20 0.38
DDB1 Q16531 1/20 0.38
CRBN Q96SW2 1/20 0.38
ALOX12 P18054 1/20 0.36
ADRA2C P18825 1/20 0.36
CLK4 Q9HAZ1 1/20 0.36
HRH3 Q9Y5N1 1/20 0.36
TSHR P16473 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10019244 0.82 MAPK1 (0.44) MAPK1SMN1; SMN2HSD17B10L3MBTL1MAOA
SCHEMBL14034630 0.79 AR (0.52) MAPK1SMN1; SMN2HSD17B10L3MBTL1MAOA
SCHEMBL14034635 0.78 AR (0.48) MAPK1SMN1; SMN2HSD17B10L3MBTL1MAOA
SCHEMBL18724536 0.78 SIRT2 (0.45) MAPK1SMN1; SMN2HSD17B10L3MBTL1MAOA
SCHEMBL11686557 0.75 MAPK1 (0.44) MAPK1SMN1; SMN2HSD17B10L3MBTL1MAOA
SCHEMBL10704412 0.74 MAOA (0.56) MAPK1SMN1; SMN2HSD17B10L3MBTL1MAOA
SCHEMBL38662707 0.72 MAOA (0.51) MAPK1L3MBTL1MAOAMAOBKIF11
SCHEMBL10019247 0.72 ALDH1A1 (0.38) MAPK1MAOAMAOBKIF11
SCHEMBL3925562 0.71 PTGS2 (0.49) MAPK1SMN1; SMN2HSD17B10L3MBTL1GSK3B
SCHEMBL23554066 0.71 DDB1 (0.45) MAPK1SMN1; SMN2HSD17B10L3MBTL1MAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8101619-B2 Phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition SOLVAY PHARMACEUTICALS B.V. (NL) 2012-01-24 US disclosed